Antibodies that potently neutralize RSV and uses thereof
US10329342B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jul 11, 2018 |
| Grant date | Jun 25, 2019 |
| Priority date | — |
| Expiry date | Jul 11, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/18534
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both group A and group B RSV. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV infection and group A and group B RSV co-infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.